Filters
cris logo
-
New search Filters
Select from list
Displayed from Show more
You have reached the maximum number of displayed search results.
All results displayed
No results are available for the search performed
Displayed from
You have reached the maximum number of displayed search results.
All results displayed
Loading results
Obtaining statistical data

Špela Gubič

Špela Gubič
no.: 53671 source: ARIS

researcher – not employed in research organisation
spela.gubicat signffa.uni-lj.si
Edit
Research activity

Code Science Field Subfield
1.09.00  Natural sciences and mathematics  Pharmacy   
Bibliography Representative bibliographic units | Personal| COBISS+
source: COBISS
source: SICRIS
Evaluation (rules)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
64.15
A''
16.94
A'
45.97
A1/2
54.52
CI10
28
CImax
21
h10
3
A1
0.25
A3
0
Data for the last 5 years (citations for the last 10 years) on April 30, 2024; A3 for period 2018-2022 (update for tender in 2023: NO)
Data for ARIS tenders ( 12.01.2024 – Project tender, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 4  28  25  6.25 
Scopus 4  30  27  6.75 
Education
source: ARIS
Level of education Professional title Study subject Faculty Year
2nd cycle master's degree  B. Sc.     SI University of Ljubljana, Faculty of Pharmacy 2019 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Research projects Legend
source: ARIS
no. Code Title Period Head
1. J1-3030  MTAvsAMR: new MultiTargeting Antibiotics against AntiMicrobial Resistance   2021 - 2024  PhD Lucija Peterlin Mašič  956 
2. L3-3177  Safety evaluation of cannabidiols and implications for public health and consumers behaviour   2021 - 2024    4,837 
3. N1-0098  Discovery and mechanism of action of novel hEag1 potassium channel lead molecules with anti-cancer activity   2019 - 2022  PhD Lucija Peterlin Mašič  885 
4. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   2022  PhD Lucija Peterlin Mašič  6,052 
5. J1-9192  New anticancer leads for emerging cancer target potassium ion channels hEag1 and its validation in lymphoma tumors   2020 - 2021  PhD Lucija Peterlin Mašič  2,197 
6. J1-8152  Inhibition of Staphylococcus aureus cell wall remodeling   2020  PhD Dušan Turk  1,978 
Confirmation required
Views history
Favourite